Text Size

Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
AIDS Malignancy Clinical Trials Consortium
ClinicalTrials.gov Identifier:
NCT00550589
First received: October 26, 2007
Last updated: May 25, 2012
Last verified: May 2012
History of Changes
Results First Received: May 24, 2011  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Anal Cancer
Precancerous Condition
Interventions: Drug: cidofovir
Genetic: DNA methylation analysis
Genetic: gene expression analysis
Genetic: polymerase chain reaction
Procedure: biopsy
Procedure: histopathologic examination

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Cidofovir 1.0% topical cidofovir cream

Participant Flow:   Overall Study
    Cidofovir  
STARTED     33  
COMPLETED     33  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Cidofovir 1.0% topical cidofovir cream

Baseline Measures
    Cidofovir  
Number of Participants  
[units: participants]
 		  33  
Age  
[units: participants]
 		 
<=18 years     0  
Between 18 and 65 years     31  
>=65 years     2  
Age  
[units: years]
Mean ± Standard Deviation 		  44  ± 8.9  
Gender  
[units: participants]
 		 
Female     9  
Male     24  
Region of Enrollment  
[units: participants]
 		 
United States     33  



  Outcome Measures

1.  Primary:   Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL)   [ Time Frame: 6 weeks after treatment discontinuation ]
  Show Outcome Measure 1

2.  Primary:   Safety and Tolerability of Topical Cidofovir as Assessed by NCI CTCAE v3.0   [ Time Frame: Every 2 weeks on study, 6 weeks after treatment discontinuation ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   Yes

3.  Secondary:   Human Papilloma Virus (HPV) DNA Type and HPV Strain Variant in Perianal HSIL and Normal Perianal Tissue   [ Time Frame: Baseline and 6 weeks after treatment discontinuation ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

4.  Secondary:   Correlation of Clinical Regression of Perianal HSIL With Clearance of HPV DNA   [ Time Frame: 6 weeks after treatment discontinuation ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

5.  Secondary:   Identification of HPV-DNA Types Present in the Anus and Cervix in Order to Compare Them With HPV-DNA Present in the Perianus   [ Time Frame: Baseline ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

6.  Secondary:   Identification of Abnormally Methylated Genes in Perianal Dysplasia   [ Time Frame: Baseline, after cycle 1, and 6 weeks after treatment discontinuation ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

7.  Secondary:   Distribution of Abnormally Methylated Genes Among HSIL, Low-grade Squamous Intraepithelial Lesions, and Normal Perianal Skin   [ Time Frame: Baseline, after cycle 1, and 6 weeks after treatment discontinuation ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No

8.  Secondary:   Changes in Gene Expression in Perianal HSIL After Exposure to Cidofovir as Assessed by RNA Microarray Analysis   [ Time Frame: Baseline, after cycle 1, and 6 weeks after treatment discontinuation ]
Results not yet posted.   Anticipated Posting Date:   No text entered.   Safety Issue:   No


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame No text entered.
Additional Description No text entered.

Reporting Groups
  Description
Cidofovir 1.0% topical cidofovir cream

Serious Adverse Events
    Cidofovir  
Total, serious adverse events    
# participants affected / at risk     3/33 (9.09%)  
Infections and infestations    
Cellulitis    
# participants affected / at risk     1/33 (3.03%)  
# events     1  
Pneumonia    
# participants affected / at risk     1/33 (3.03%)  
# events     1  
Skin and subcutaneous tissue disorders    
Dermatology/skin    
# participants affected / at risk     2/33 (6.06%)  
# events     2  




  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Jeannette Lee
Organization: Statistical Center of AIDS Malignancy Consortium
phone: (501) 526-6712
e-mail: jylee@uams.edu


No publications provided by AIDS Malignancy Clinical Trials Consortium

Publications automatically indexed to this study:


Responsible Party: AIDS Malignancy Clinical Trials Consortium
ClinicalTrials.gov Identifier: NCT00550589     History of Changes
Other Study ID Numbers: CDR0000570720, U01CA121947, AMC-046
Study First Received: October 26, 2007
Results First Received: May 24, 2011
Last Updated: May 25, 2012
Health Authority: United States: Federal Government
United States: Food and Drug Administration
United States: Institutional Review Board